Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Glenmark Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2026 was 12.72%.
Glenmark Pharmaceuticals (BOM:532296) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
(1) Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Glenmark Pharmaceuticals (BOM:532296) has a ROCE % of 12.72% as of Mar. 2026.
Is Glenmark Pharmaceuticals' ROCE % too high?
Glenmark Pharmaceuticals' current ROCE % is 12.72%. The Drug Manufacturers industry median ROCE % is 7.04. Glenmark Pharmaceuticals' value of 12.72% is 80.7% above this industry median. Overall, Glenmark Pharmaceuticals has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Glenmark Pharmaceuticals' ROCE % compare to ZTS?
Glenmark Pharmaceuticals' ROCE % of 12.72% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.04. Glenmark Pharmaceuticals' value of 12.72% is 80.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.04, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Glenmark Pharmaceuticals's current ROCE % of 12.72% is 80.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Glenmark Pharmaceuticals's current ROCE % is 12.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glenmark Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Glenmark Pharmaceuticals (BOM:532296) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,986.60, compared to a current price of ₹2,184.90 — trading 10% above its estimated fair value. The current ROCE % is 12.72% and 80.7% above the Drug Manufacturers industry median of 7.04. Glenmark Pharmaceuticals' overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Glenmark Pharmaceuticals (BOM:532296), the current ROCE % is 12.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Glenmark Pharmaceuticals (BOM:532296) Overvalued in 2026?
Based on GuruFocus' analysis, Glenmark Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹2,184.90 is trading 10% above its estimated GF Value™ of ₹1,986.60.
GuruFocus considers Glenmark Pharmaceuticals to be Fairly Valued.
Key valuation signals for BOM:532296:
ROCE %: 12.72%
GF Value™: ₹1,986.60 vs. price of ₹2,184.90 (10% above fair value)
Industry Position: 80.7% above the Drug Manufacturers median
No single metric tells the full story. See the BOM:532296 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities. It has a business presence in different therapeutic areas such as dermatology, respiratory, oncology, diabetes, cardiovascular, and oral contraceptives among others. Geographically, it derives key revenue from India and the rest from North America, Latin America, Europe and the Rest of the world.
88GF Score
Get the complete analysis for BOM:532296
ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532296 has been successfully added to your 
